Dacatec Drug Interactions

Coadministration of Dacatec (Daclatasvir) can alter the concentration of other medicinal products and other medicinal products may alter the concentration of Daclatasvir.
The dose of Dacatec (Daclatasvir) should be reduced to 30 mg once daily when coadministered with boceprevir, telaprevir, atazanavir/ritonavir, cobicistat, atazanavir/cobicistat, clarithromycin, telithromycin, ketoconazole or other strong inhibitors of CYP3A4.
The dose of Dacatec (Daclatasvir) should be increased to 90 mg once daily when coadministered with efavirenz.
Due to the lack of data, coadministration of Dacatec (Daclatasvir) and etravirine or nevirapine is not recommended.
Administration of Dacatec (Daclatasvir) with erythromycin may result in increased concentrations of Daclatasvir. Caution is advised.
Safety monitoring is advised when initiating treatment with Dacatec (Daclatasvir) in patients receiving dabigatran etexilate or other intestinal P-gp substrates that have a narrow therapeutic range.
Coadministration of Dacatec (Daclatasvir) with carbamazepine, oxcarbazepine, phenobarbital, phenytoin or other strong inducers of CYP3A4 is contraindicated. Modest increases in concentrations of Daclatasvir are expected, but no dose adjustment of Dacatec (Daclatasvir) or fluconazole is required.
Coadministration of Dacatec (Daclatasvir) with rifampicin, rifabutin, rifapentine or other strong inducers of CYP3A4 is contraindicated.
Digoxin should be used with caution when coadministered with Dacatec (Daclatasvir). The lowest dose of digoxin should be initially prescribed. The serum digoxin concentrations should be monitored and used for titration of digoxin dose to obtain the desired clinical effect.
Use only if no other alternative is available. Close monitoring is recommended if this medicinal product is administered with Dacatec (Daclatasvir) in combination with sofosbuvir.
Administration of Dacatec (Daclatasvir) with any of calcium channel blockers may result in increased concentrations of Daclatasvir. Caution is advised.
Administration of Dacatec (Daclatasvir) with verapamil may result in increased concentrations of Daclatasvir. Caution is advised.
Coadministration of Dacatec (Daclatasvir) with systemic dexamethasone or other strong inducers of CYP3A4 is contraindicated.
Coadministration of Dacatec (Daclatasvir) with St. John's wort or other strong inducers of CYP3A4 is contraindicated.
An oral contraceptive containing ethinylestradiol 35 μg and norgestimate 0.180/0.215/0.250 mg is recommended with Dacatec (Daclatasvir). Other oral contraceptives have not been studied.
Caution should be used when Dacatec (Daclatasvir) is coadministered with rosuvastatin or other substrates of OATP 1B1 or BCRP.